Immunocore Reports Q3 2026 Revenue of $102.2 Million and $14.2 Million Net Loss
Immunocore reported Q3 2026 revenue of $102.2M, down from $103.7M a year earlier, and a net loss of $14.2M. Nine-month revenue rose to $324.8M. The company also updated progress on its melanoma, infectious disease, and autoimmune programs.
How this was made
The 30-second read
Why it matters
The earnings release shows a revenue decline and deeper loss, which may pressure the share price in the short term.
Market read
Primary earnings disclosure for a listed biotech; relevant for traders tracking sector momentum and pipeline milestones.
What to watch
Cash balance of $901.3M provides runway; upcoming Phase 3 OS data in Q2 2027 may offset short‑term weakness.
Background
Immunocore is a cell‑therapy biotech focused on T‑cell redirecting immunotherapies, listed on Nasdaq under IMCR.
Ticker impact
Immunocore reported Q3 2026 revenue of $102.2M, down YoY, and a net loss of $14.2M, marking the first public disclosure of these earnings figures.
likely modest downside as investors price in weaker revenue and higher loss
The company posted lower revenue and a larger net loss compared with the prior year, which typically triggers a sell‑off in biotech stocks.
Market effects
Biotech sector may see slight pullback as earnings miss highlights execution risk.
UK/US biotech investors may reassess near‑term pipelines.
Limited to investors with exposure to Immunocore and similar cell‑therapy firms.
Counterpoint
Despite the miss, the company's expanding pipeline and upcoming data readouts could support a rebound.
Key entities
- companyImmunocore Holdings plc
Biotech firm developing T‑cell redirecting therapies.